[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353914-105":59,"doc-detail-353914-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","screening-of-hepatocellular-carcinoma-in-hepatic-cirrhosis-patients-by-a-novel-blood-based-multi-omiics-test","Screening of Hepatocellular Carcinoma in Hepatic Cirrhosis Patients by a Novel Blood-Based Multi-Omiics Test","","Hepatocellular carcinoma (HCC) screening in hepatic cirrhosis (HC) patients currently relies on ultrasound plus alpha-fetoprotein (US+AFP), but early-stage detection remains limited by sensitivity. This study evaluates a novel multi-omics blood test, HCCscreen, including methylation, AFP, DCP, and mutations, against the standard US+AFP approach. In a prospective cohort, HCCscreen achieved high sensitivity (86.3%) with strong negative predictive value (98.6%) and superior early-stage detection, supported by an AUC of 0.87.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/screening-of-hepatocellular-carcinoma-in-hepatic-cirrhosis-patients-by-a-novel-blood-based-multi-omiics-test/353914/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/screening-of-hepatocellular-carcinoma-in-hepatic-cirrhosis-patients-by-a-novel-blood-based-multi-omiics-test/353914.png","ImageObject",300,407,{"name":92,"@type":93},"Jacob","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-15","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What limitation does the current US+AFP screening approach have for HCC?","Question",{"text":112,"@type":113},"US+AFP has limited sensitivity, especially for detecting early-stage HCC in patients with hepatic cirrhosis.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the HCCscreen test evaluated in this study?",{"text":117,"@type":113},"A prospective screening study enrolled 650 cirrhosis patients; blood samples were collected before confirmation by imaging and/or pathology, then performances of HCCscreen, individual markers, and US+AFP were compared.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the results show about HCCscreen’s performance versus US+AFP in early-stage HCC?",{"text":121,"@type":113},"HCCscreen demonstrated significantly higher positive detection rate than US+AFP in early-stage HCC (BCLC-0 and clinical stage I), with overall superior accuracy (AUC 0.87).","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},353914,1790192928,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":14,"preview_urls":146},962084931830,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Screening of Hepatocellular Carcinoma in Hepatic Cirrhosis Patients by a Novel Blood-Based Multi-Omics Test  \nTechnology in Cancer Research & Treatment  \nVolume 25: 1-15 © The Author(s) 2026 Article reuse guidelines:  \n[sagepub.com/journals-permissions](sagepub.com/journals-permissions)[ ](sagepub.com/journals-permissions)[DOI: 10.1177/15330338261435022](DOI: 10.1177/15330338261435022)[ ](DOI: 10.1177/15330338261435022)[journals.sagepub.com/home/tct](journals.sagepub.com/home/tct)  \nLei Chen, MD 1,2, Jun Liu, MD 1,2, Mengcheng Long, MD 1,2, and Pinghai Hu, MD 1,2   \nAbstract  \nIntroduction: Hepatocellular carcinoma (HCC) screening in patients with hepatic cirrhosis (HC) relies on ultrasound and alpha-fetoprotein (US+AFP), which has limitations in sensitivity, particularly for early-stage HCC detection. This study aims to evaluate the performance of a novel multi-omics blood test, HCCscreen, with its individual components (methylation, AFP, Des-γ-Carboxy Prothrombin (DCP), mutations) and the standard US+AFP for HCC screening in a hepatic cirrhotic population.  \nMethods: A total of 5078 patients with known high-risk for HCC were recruited. A prospective screening study was conducted on 650 patients with hepatic cirrhosis identiﬁed by ultrasound. Blood samples were collected from all patients before the conﬁrmation of diagnosis by imaging and/or pathological examinations. The performance of HCCscreen, individual markers and US + AFP were calculated and compared. Statistics was performed with Graphpad Prism 5.0.  \nResults: HCCscreen exhibited a sensitivity of 86.3% at a speciﬁcity of 81.3%, with a positive predictive value (PPV) of 28.2% anda negative predictive value (NPV) of 98.6%. The positive likelihood ratio (LR+) was 4.61 and the negative LR (LR-) was 0.17. The positive detection rate (PDR) for all markers increased with more advanced HCC stages, whether Barcelona Clinic Liver Cancer (BCLC) or clinical staging. Among the single-omics, methylation showed the highest PDR, followed by AFP, DCP and mutations. HCCscreen demonstrated superior overall performance with an AUC of 0.87, outperforming individual markers like methylation (AUC = 0.76), AFP (AUC = 0.83), and DCP (AUC = 0.77). Crucially, HCCscreen’s PDR was signiﬁcantly higher than US+AFP in early-stage HCC (BCLC-0 and clinical stage I). Furthermore, while AFP’s PDR varied signiﬁcantly by sex, HCCscreen’s performance remained consistent across all demographics. Correlation analysis revealed a signiﬁcant association only between the HCCscreen score and the methylation score.  \nConclusions: The multi-omics approach of HCCscreen signiﬁcantly enhances early HCC detection in patients with hepatic cirrhosis compared to both its individual components and the current standard of US+AFP. Its robust and consistent performance across patient demographics underscores its potential as a superior tool for population-wide early HCC screening.  \nKeywords  \nhepatocellular carcinoma, screening, cirrhosis, methylation, mutation, AFP, DCP, PIVKA-II  \nReceived: 25 October 2025; revised: 12 February 2026; accepted: 6 March 2026  \nIntroduction  \nHepatocellular carcinoma (HCC) is the ﬁfth most common and the third most deadly cancer, with a 5-year survival rate of only 12. 1% . 1,2 The most effective way to improve the survival rate of HCC is to detect the lesion at an early stage and provide timely radical treatment.3 Therefore, the application of effective screening methods and early intervention is crucial for the prevention and treatment of HCC.  \nCirrhosis is a crucial step in the progression from various types of hepatitis and liver diseases to HCC. Taking hepatitis  \n1 Department of Hepatopancreatobiliary, The First People’s Hospital of Yunnan Province, Kunming, Yunnan, China  \n2The Afﬁliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, China  \nCorresponding Author:  \nPinghai Hu, MD, Department of Hepatopancreatobiliary, The First People’s Hospital of Yunnan P","cbCaisxuv3seCJVw","https://ap.wps.com/l/cbCaisxuv3seCJVw","pdf",2827268,15,"English","# Abstract\n## Introduction\n## Methods\n## Results\n## Conclusions\n## Keywords\n# Article Sections\n## Introduction","[{\"question\":\"What limitation does the current US+AFP screening approach have for HCC?\",\"answer\":\"US+AFP has limited sensitivity, especially for detecting early-stage HCC in patients with hepatic cirrhosis.\"},{\"question\":\"How was the HCCscreen test evaluated in this study?\",\"answer\":\"A prospective screening study enrolled 650 cirrhosis patients; blood samples were collected before confirmation by imaging and/or pathology, then performances of HCCscreen, individual markers, and US+AFP were compared.\"},{\"question\":\"What did the results show about HCCscreen’s performance versus US+AFP in early-stage HCC?\",\"answer\":\"HCCscreen demonstrated significantly higher positive detection rate than US+AFP in early-stage HCC (BCLC-0 and clinical stage I), with overall superior accuracy (AUC 0.87).\"}]","Screening of Hepatocellular Carcinoma in Hepatic Cirrhosis Patients by a Novel Blood-Based Multi-Omiics Test | PDF",1790107885,38,[147,151],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/fda0314e600b9fc2e0225a057c14fd68.webp",983,1276,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/c97d4de00239a2ed78a308a9ae956500.webp",982,1275]